Parkman Healthcare Partners’s Annexon ANNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.66M Sell
641,029
-32,984
-5% -$182K 0.37% 62
2026
Q1
$3.73M Buy
674,013
+72,811
+12% +$410K 0.39% 70
2025
Q4
$3.02M Buy
601,202
+195,249
+48% +$746K 0.29% 80
2025
Q3
$1.24M Buy
405,953
+1,759
+0.4% +$4.37K 0.13% 84
2025
Q2
$970K Buy
404,194
+52,758
+15% +$106K 0.11% 84
2025
Q1
$678K Buy
351,436
+20,587
+6% +$68.5K 0.08% 87
2024
Q4
$1.7M Buy
330,849
+2,236
+0.7% +$13.8K 0.23% 78
2024
Q3
$1.95M Buy
328,613
+1,768
+0.5% +$10.5K 0.25% 75
2024
Q2
$1.6M Sell
326,845
-19,842
-6% -$103K 0.21% 77
2024
Q1
$2.49M Buy
+346,687
New +$1.8M 0.31% 79

Other funds holding ANNX

Parkman Healthcare Partners's ANNX Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its Annexon (ANNX) stake by 4.9% in Q2 2026, selling an estimated $182K and leaving 641,029 shares worth $3.66M. The position accounts for 0.37% of the portfolio, ranked #62.

Parkman Healthcare Partners first reported a position in ANNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.73M in Q1 2026. 216 funds tracked by Wall St. Rank hold ANNX as of Q2 2026.

  • Parkman Healthcare Partners held 641,029 shares of Annexon worth $3.66M as of Q2 2026.
  • Parkman Healthcare Partners sold 32,984 Annexon shares in Q2 2026, an estimated $182K.
  • Annexon made up 0.37% of Parkman Healthcare Partners's portfolio in Q2 2026, its #62 holding.
  • Parkman Healthcare Partners first reported a position in Annexon in Q1 2024 and has held it in 10 quarters since.
  • Parkman Healthcare Partners's Annexon position peaked at $3.73M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Annexon as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.